Development of Assays for Detecting Significant Prostate Cancer Based on Molecular Alterations Associated with Cancer in Non-Neoplastic Prostate Tissue
Annual rept. 30 Sep 2014-29 Sep 2015
MAYO CLINIC ROCHESTER MN
Pagination or Media Count:
The goal of this project is to develop biopsy based assays to assess the probability that patients with a negative biopsy or with a prostate cancer CaP Gleason score 6 GS6 biopsy actually have significant CaP of Gleason score 7 or higher which was missed during the biopsy evaluations due to insufficient sampling. Experimental design includes discovery and validation steps. In the discovery step, we have generated a sizable set of close to 200 gene expression and methylation sequencing data from High grade PIN HGPIN collected by laser captured microdissection LCM and bulk normal samples. Our data set was further boosted through collaboration with another Mayo investigator. Through an RFA by the Mayo Clinomics Program, we completed gene expression and methylation sequencing of indolent and significant tumor samples ca. 60 totals. Based on our previous experience, genomic profiles of tumor can provide crucial clues in field effect biomarker selection and therefore we anticipate these data will be important in the success of this project. We are very close to the completion of collecting RNADNA from the FFPE samples in the validation step. We expect that in the coming year we will be able to validate our findings in the discovery step and develop biopsy based models that will be useful in clinical settings.
- Medicine and Medical Research